Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2025-11-21 Report Publication Anno…
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Notice of Results
Report Publication Announcement Classification · 100% confidence The document is an announcement from Fusion Antibodies plc regarding the upcoming release of its interim results and an invitation to an investor presentation. It does not contain the actual financial results, but rather serves as a notification of when those results will be published and how investors can participate in a follow-up call. Following the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-11-21 English
OptiMAL Library video
Regulatory Filings Classification · 100% confidence The document is a 'Reach' announcement, which is explicitly defined as a non-regulatory press release service for media-only news. It describes a promotional video about the company's 'OptiMAL Library' technology and provides a link to the company's investor hub. Since it does not contain mandatory regulatory disclosures, financial results, or specific corporate actions, it falls under the fallback category of Regulatory Filings (RNS) as it is distributed via the RNS platform.
2025-11-13 English
OptiMAL® R&D Update
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement (RNS) from Fusion Antibodies plc regarding an R&D update for their OptiMAL platform. It details technical progress, collaboration status with the NCI, and commercial launch timelines. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication announcement (RPA) as it contains substantive operational news. Therefore, it is classified as a general regulatory filing.
2025-11-03 English
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings' filed by Fusion Antibodies PLC. It explicitly details a change in share ownership by Maven Capital Partners UK LLP, crossing a reporting threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-10-27 English
Result of AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an RNS announcement from Fusion Antibodies plc titled 'Result of AGM'. It explicitly states that the annual general meeting was held and that all resolutions were duly passed. While it mentions that full details of voting results are available on the company's website, the document itself serves as the official notification of the voting outcome. According to the filing definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the correct category for official results from shareholder votes at a general meeting.
2025-10-16 English
AGM statement and H1 trading update
AGM Information Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Fusion Antibodies plc. It serves as an 'AGM statement and H1 trading update'. While it contains financial highlights (H1 trading update), it is primarily an announcement released via a regulatory service rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of information provided at an AGM and a trading update, which fits best under the 'Earnings Release' (ER) category as it provides initial highlights of financial performance for the period, or 'Regulatory Filings' (RNS) as a fallback. Given the specific content regarding trading performance and the AGM context, 'ER' is the most accurate classification for a trading update.
2025-10-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.